Search clinical trials for: Phosphodiesterase 4 Inhibitors

Total 66553 results

Professor Mikkel Østergaard
Celgene Corporation; The Danish Rheumatism Association; The Danish Psoriasis...

Unknown

Danish Population-based Assessment of Psoriasis and Psoriatic Arthritis (DANPAPP) (DANPAPP)

Psoriasis | Psoriatic Arthritis

Denmark
Sunnybrook Health Sciences Centre
Celgene; Sunnybrook Research Institute

Withdrawn

Apremilast - Oral Lichen Planus Trial (APOLP)

Oral Lichen Planus

Canada
Amgen

Completed

A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp (STYLE)

Psoriasis

United States, Canada
Amgen

Completed

Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis (UC)

Ulcerative Colitis

Russian Federation, United States, France, Australia, Czechia, New Zealand, Germany, Italy, Poland, Hungary, Netherlands, Ukraine, Bulgaria, Canada
NHS Greater Glasgow and Clyde

Completed

Immune Metabolic Associations in Psoriatic Arthritis (IMAPA)

Psoriasis | Psoriatic Arthritis

United Kingdom
Icahn School of Medicine at Mount Sinai
Celgene

Completed

Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo

Vitiligo

United States
Baylor Research Institute

Completed

The Controlled Trial of Apremilast for Rheumatoid Arthritis Treatment (CARAT)

Rheumatoid Arthritis

United States
Saint Petersburg State University, Russia

Recruiting

Efficacy and Safety of Focused Shockwave Therapy Plus Tadalafil vs Tadalafil Alone in Patient With Erectile Dysfunction

Erectile Dysfunction

Russian Federation
Amgen

Recruiting

Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease (BEAN)

Behçet Disease

Spain, United Kingdom, Turkey, France, Greece, Italy, Israel, Switzerland
Amgen

Completed

A Study to Describe the Characteristics of Patients Treated With Apremilast for Plaque Psoriasis in Italian Routine Clinical Practice (DARWIN)

Plaque Psoriasis

Italy
Amgen

Active, not recruiting

A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

Psoriasis

Belgium, Spain, United States, Czechia, Italy, Russian Federation, Canada, France, Israel
Amgen

Completed

A Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Adults With Manifestations of Plaque Psoriasis and Impaired Quality of Life (EMBRACE)

Psoriasis

France, Italy, Spain, United Kingdom, Switzerland, Germany
Amgen

Completed

A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease

Behcet Syndrome

United States, Turkey
Amgen

Completed

A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis

Psoriasis

Canada, Spain, United States, Germany
Tanja Todberg, MD

Unknown

Apremilast as Anti-pruritic Treatment in Patients With Prurigo Nodularis

Prurigo Nodularis

Denmark
University of South Florida

Withdrawn

Treatment With Apremilast in Patients With Psoriatic Arthritis

Psoriatic Arthritis

United States
Amgen

Recruiting

A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO) (ESSENCE)

Plaque Psoriasis

China
Takeda

Recruiting

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

Plaque Psoriasis

United States, Canada
Amgen

Recruiting

Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis (PEAPOD)

Active Juvenile Psoriatic Arthritis

Spain, Turkey, Belgium, France, Greece, Italy, United Kingdom, Austria, Germany, Netherlands, Poland, Romania, Lithuania, South Africa, Portugal
University Hospital, Rouen

Not yet recruiting

Randomized Double Blind Controlled Trial Comparing the Safety and Efficacy of Apremilast Versus Placebo in Severe Forms of Recurrent Aphthous Stomatitis (PREMS)

Recurrent Aphtous Stomatitis
Amgen

Active, not recruiting

Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplantar Pustulosis (PPP)

Palmoplantar Pustulosis

Japan
Amgen

Completed

A Study to Evaluate the Impact of Apremilast on Magnetic Resonance Imaging (MRI) Outcomes in Adults With Psoriatic Arthritis (MOSAIC)

Psoriatic Arthritis

Spain, Belgium, Denmark, United States, Germany, Russian Federation, Austria, United Kingdom, Canada, Italy, Switzerland
Technical University of Munich
Celgene Corporation

Completed

An Investigator-initiated Study of Apremilast to Demonstrate Efficacy Nummular Eczema (APREMINUM)

Eczema | Nummular Eczema | Dermatitis Eczema | Nummular Dermatitis

Germany
Hospital de Granollers
Hospital de Sant Joan Despí Moisès Broggi

Completed

Quality of Life and Ultrasonographic Assessment of Nail Psoriasis After Treatment With Apremilast (JUST Study) (JUST)

Nail Psoriasis

Spain
Amgen

Completed

Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis

Psoriasis-Type Psoriasis | Plaque-Type Psoriasis

United States
Innovaderm Research Inc.
Celgene

Completed

Apremilast in Palmo-Plantar Psoriasis

Palmo-plantar Psoriasis

United States, Canada
University Hospitals Cleveland Medical Center
Celgene Corporation

Completed

Safety and Efficacy of CC-10004 for Prurigo Nodularis

Prurigo Nodularis

United States
Kenneth Peters, MD
Celgene Corporation

Completed

CC-10004 For The Treatment Of Vulvodynia

Vulvodynia

United States
Duke University

Withdrawn

Apremilast for Chronic Plaque Psoriasis (CPP) Patients Who Have Failed One Course of Biologic Therapy

Chronic Plaque Psoriasis

United States
Bristol-Myers Squibb

Recruiting

A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect) (RePhlect)

Plaque Psoriasis

Japan
Takeda

Completed

Safety and Pharmacokinetic Profile of Udenafil in Healthy Mexican Adults

Erectile Dysfunction | Phosphodiesterase 5 Inhibitor

Mexico
Warner Chilcott

Completed

Treatment of Erectile Dysfunction I

Erectile Dysfunction

United States
Amgen

Recruiting

A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis

Plaque Psoriasis

United States
Amgen

Recruiting

A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis

Juvenile Psoriatic Arthritis | Behçet's Disease

Spain, Israel, Turkey, Greece
Amgen

Completed

A Phase 3B, Open-label, Single-arm Study of the Efficacy and Safety of Apremilast, in Subjects With Plaque Psoriasis That is Not Adequately Controlled by Topical Therapy

Plaque Psoriasis

Japan, Germany
Amgen

Completed

A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behçet's Disease

Behçet's Syndrome

United States, Korea, Republic of, Israel, Italy, Turkey, France, Germany, Greece, Lebanon, Japan
Amgen

Completed

Study to Evaluate the Pharmacokinetics of Single and Multiple Doses of Apremilast in Healthy Adult Male Korean Subjects

Pharmacokinetics

Korea, Republic of
Amgen

Completed

Effect of Food on the Pharmacokinetics of Apremilast (CC-10004) in Healthy Adults

Healthy Volunteer

United States
Amgen

No longer available

Expanded Access for CC-10004

Bechet's Disease

United States
Pfizer

Terminated

Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke

Ischemic Stroke

United States, Taiwan, Korea, Republic of, India, Germany, Canada, France, Bulgaria, Czech Republic, Hungary
Asan Medical Center
Dong-A Pharmaceutical Co., Ltd.

Completed

Clinical Study to Investigate the Safety and Pharmacokinetics of Udenafil Tablet in Renal Impaired Male Patients (DA8159_RI_I)

Kidney Diseases | Urologic Diseases | Renal Insufficiency

Korea, Republic of
Brigham and Women's Hospital
Johns Hopkins University; National Institute on Aging (NIA); Rutgers University

Completed

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - PDE5 Inhibitors vs Endothelin Receptor Antagonist

Pulmonary Arterial Hypertension

United States
AbbVie

Completed

Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy

Psoriasis

United States, Canada, Germany, Israel, Poland
Amgen

Completed

An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis (DISCREET)

Psoriasis

United States, Belgium, Italy, France, Germany, Puerto Rico, Canada
Amgen

Terminated

Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

Psoriasis

United States, Belgium, Spain, Czechia, Canada, Italy, Israel, France, Netherlands, Russian Federation
The Scripps Research Institute
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Completed

Medication Development in Alcoholism: Apremilast Versus Placebo

Alcohol Use Disorder

United States
Imperial College London
Celgene Corporation

Completed

Spondylitis Trial of Apremilast for Better Rheumatic Therapy (START)

Ankylosing Spondylitis

United Kingdom
Mezzion Pharma Co. Ltd
National Heart, Lung, and Blood Institute (NHLBI)

Unknown

A Extension Study of Udenafil in Adolescents (FUELExten)

Functional Single Ventricle Heart Disease

United States, Korea, Republic of, Canada
Mezzion Pharma Co. Ltd
National Heart, Lung, and Blood Institute (NHLBI); Pediatric Heart Network

Completed

Pharmacokinetic/Pharmacodynamic Study of Udenafil in Adolescents

Single Ventricle Heart Disease After Fontan Surgery

United States, Canada
Asan Medical Center
SK Chemicals Co., Ltd.

Completed

Clinical Study to Investigate the Safety and Pharmacokinetics of SK3530 Tablet in Renal Impaired Male Patients (SK3530_RI_I)

Kidney Diseases | Urologic Diseases | Renal Insufficiency

Korea, Republic of

3

Subscribe